In this review, the value of functional imaging [positron emission tomography (PET)/single-
photon emission computed tomography (SPECT)] in drug development is considered …

Positron emission tomography (PET) is an extensively used nuclear functional imaging
technique, especially for central nervous system (CNS) and oncological disorders. Currently …

Molecular imaging methods such as positron emission tomography (PET) are increasingly
involved in the development of new drugs. Using radioactive tracers as imaging probes, PET …

As drug discovery and development in Neuroscience push beyond symptom management
to disease modification, neuroimaging becomes a key area of translational research that …

In central nervous system drug discovery programs, early development of new chemical
entities (NCEs) requires a multidisciplinary strategy and a translational approach to obtain …

Positron emission tomography (PET) is a non-invasive technology of nuclear medicine that
has sensitivity for tracing low picomolar concentrations of radiolabeled molecules in the …

The goal of any early central nervous system (CNS) drug development program is always to
test the mechanism and not the molecule in order to support additional research investments …

Positron emission tomography (PET) is an in vivo molecular imaging tool which is widely
used in nuclear medicine for early diagnosis and treatment follow-up of many brain …

The discovery and development of central nervous system (CNS) drugs is an extremely
challenging process requiring large resources, timelines, and associated costs. The high …

Human in vivo molecular imaging with positron emission tomography (PET) enables a new
kind of 'precision pharmacology', able to address questions central to drug development …